Neogenomics (NEO) Cash from Operations Growth (3y) (2013 - 2026)
Neogenomics (NEO) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 11.33% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | -9.46% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 20.12% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | -11.38% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 11.55% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 35.64% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 24.17% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 5.18% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 10.37% |
| 10 | Neogenomics | 2.05 Bn | 1.90 Bn | 91.88 Mn | 146.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 146.04% |
| Mar 31, 2026 | 13.77% |
| Dec 31, 2025 | 33.22% |
| Sep 30, 2025 | 36.55% |
| Jun 30, 2025 | 47.30% |
| Mar 31, 2025 | 4.46% |
| Dec 31, 2024 | 35.64% |
| Sep 30, 2024 | 47.21% |
| Jun 30, 2024 | 128.91% |
| Mar 31, 2024 | -139.43% |
| Dec 31, 2023 | 43.77% |
| Sep 30, 2023 | -131.77% |
| Jun 30, 2023 | -41.32% |
| Mar 31, 2023 | -22.33% |
| Dec 31, 2022 | -45.76% |
| Sep 30, 2022 | -42.16% |
| Jun 30, 2022 | -53.26% |
| Mar 31, 2022 | -89.11% |
| Dec 31, 2021 | -48.58% |
| Sep 30, 2021 | -43.04% |